SciBase Board Approves Warrant Repurchase and Rights Issue Strategy to Boost Capital Structure

SciBase Moves Ahead with Capital Strategy

SciBase Holding AB, a pioneering company in dermatological diagnostics, is set to undertake significant capital-raising initiatives. On November 7, 2025, the company's Board of Directors announced plans to offer a repurchase of all outstanding warrants from series TO 2 and to initiate a rights issue aimed at raising approximately SEK 83 million. This strategic move reflects SciBase's commitment to enhancing its financial stability and supporting future growth.

Overview of the TO 2 Offer

The TO 2 Offer will enable holders of the series TO 2 warrants—totaling 498,534,835—to exchange two warrants for one new share in the company. With a potential issuance of up to 249,267,417 new shares, this repurchase could result in approximately 37.6% dilution to current shareholders.

A substantial portion of the warrants, about 74%, has already been pledged for acceptance by key investors, underscoring confidence in SciBase’s direction. The acceptance period for the TO 2 Offer is expected to run from December 8, 2025, to January 8, 2026, contingent on approval from an extraordinary general meeting scheduled for December 5, 2025.

Details of the Rights Issue

Complementing this initiative, SciBase is also planning a rights issue to enhance its capital base further. Each existing shareholder will receive one subscription right for each share they hold, allowing them to subscribe for new shares at a set price of SEK 0.20. The total funds raised through this rights issue are crucial for financing ongoing commercialization efforts, particularly in the competitive US market.

The rights issue is covered by commitments of about SEK 64.3 million, indicating substantial backing from existing shareholders; this represents 78% of the target amount. Noteworthy contributors include Castle Bioscience and Haga Gruppen, who have committed significant amounts to secure their interests and actively participate in the proceeding.

Strategic Implications

CEO Pia Renaudin emphasized the positive trajectory of SciBase, particularly its growth in both the German and US markets, stating, "The upcoming Rights Issue will provide runway for continued growth that will set us on a course towards profitability." The company’s focus not only remains on melanoma diagnostics but is also expanding its horizons in the treatment of other skin diseases, reflecting a sturdy growth strategy built on innovation and collaboration.

The funds from the rights issue are expected to sustain the company well into 2027, thereby facilitating its commercial ambitions and drive for product development. This includes investments into increasing production capacity for their flagship product, Nevisense—a non-invasive tool for skin disease prevention through electrical impedance spectroscopy.

Conclusion

SciBase's proactive approach through the TO 2 Offer and rights issue positions the company for enhanced financial resilience and growth. These measures are seen as pivotal for further building its market presence, particularly in the US, where there has been a remarkable 200% revenue growth over the past nine months amid increased market penetration. Ultimately, these initiatives will empower SciBase to bolster its competitive edge in dermatology and advance its mission of improving skin health outcomes worldwide.

For further details on the TO 2 Offer, rights issue, and the overall strategic direction of SciBase Holding AB, stakeholders can look for forthcoming announcements as the acceptance periods approach. This comprehensive strategy aligns with the company’s long-term vision to leverage advances in AI and EIS technology for dermatology, ensuring a significant impact in early disease detection and preventive care.